What question did this study set out to answer?

To assess the safety, tolerability, and pharmacokinetics of bisnorcymserine in human subjects.

May 16, 2026Open Access

A phase 1, safety, tolerability, and pharmacokinetics study of bisnorcymserine, a highly selective inhibitor of butyrylcholinesterase

Key Points

To assess the safety, tolerability, and pharmacokinetics of bisnorcymserine in human subjects.
Phase I, first-in-human study
Single oral doses of 40 mg, 80 mg, and 120 mg
Assessment of pharmacokinetics and tolerability parameters.
BNC safe and well tolerated at doses up to 120 mg
Mean half-life ranged from 5.5 to 7 hours
Pharmacokinetic parameters consistent across multiple doses.

Abstract

(SD) were 1.8 (1.0-5.0) hr and 13.94 (7.64) ng/mL for the 40 mg dose, 1.8 (1.5-5.0) hr and 18.54 (6.44) ng/mL for the 80 mg dose, and 2 (1.0-4.5) hr and 20.93 (5.00) ng/mL for the 120 mg dose. The mean half-life of BNC ranged from 5.5 to 7 h. BNC was safe and well tolerated when administered as a single oral dose of up to 120 mg. This first-in-human, phase I study permits further investigation of this drug as a potential symptomatic treatment for AD. ClinicalTrials.gov, NCT01747213.

Read Full Paperexternally

Bookmark

View Full Paper

Cite This Study

Tzieras et al. (Wed,) studied this question.

synapsesocial.com/papers/6a080a9fa487c87a6a40c820 https://doi.org/https://doi.org/10.1016/j.neurot.2026.e00918

Bookmark

View Full Paper